Trials / Unknown
UnknownNCT04861467
Camrelizumab as a Maintenance Therapy After Chemoradiation in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma
A Randomized, Open Study of Camrelizumab vs Placebo as a Maintenance Therapy After Chemoradiation in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 155 (estimated)
- Sponsor
- Chinese Academy of Medical Sciences · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study was to evaluate the efficacy and safety of Camrelizumab as maintenance therapy in newly diagnosed locally advanced head and neck squamous cell carcinoma subjects after chemoradiation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Camrelizumab | IV |
Timeline
- Start date
- 2021-06-01
- Primary completion
- 2025-07-31
- Completion
- 2025-12-31
- First posted
- 2021-04-27
- Last updated
- 2021-04-27
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04861467. Inclusion in this directory is not an endorsement.